Home / Volume 5, Issue 2 / Dose of Indemnity for the COVID-19 Vaccine Manufacturers… Open access · CC BY-NC 4.0
Research Paper Volume 5 Issue 2 1367 - 1373 April 17, 2022

Dose of Indemnity for the COVID-19 Vaccine Manufacturers and it’s Effectiveness in India

Lead author · Corresponding
Shreya Singh
Student in India.
View PDF Full text DOIhttps://doij.org/10.10000/IJLMH.112939
Abstract

Amid the deadly chaos caused due to the Coronavirus, vaccines emerged as a boon for humanity. These vaccines have been produced at lightning speed. The leading vaccine manufacturers have been leading the vaccine industry, such as United States biotechnology company Moderna and German pharmaceutical company Pfizer. Further, the vaccines produced by these companies have been proven to be 95% effective in reducing the mortality rate due to Coronavirus. As the vaccines produced by these companies are in high demand, developed nations like the United States of America and the United Kingdom have granted indemnity to these companies from civil liability. In India, there are no such legal arrangements for vaccine manufacturers to escape criminal or civil liability. Thus, the purpose of this paper is to examine the viability of indemnity contracts with the vaccine manufacturers in India, considering that a similar demand for indemnity clause has been made by the Serum Institute of India, which has been producing vaccines for Coronavirus on a large scale in India.

Type
Research Paper
Information
International Journal of Law Management and Humanities, Volume 5, Issue 2, Page 1367 - 1373
DOI: https://doij.org/10.10000/IJLMH.112939
Creative Commons
CC BY-NC 4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution–NonCommercial 4.0 International (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/), which permits remixing, adapting, and building upon the work for non-commercial use, provided the original work is properly cited.
Copyright
Copyright © IJLMH 2026
Disclaimer
The views and opinions expressed in this manuscript are those of the author(s) alone and do not reflect the views, policies, or position of the Journal.

Export citation


        
📢 Call for Papers — Volume IX Issue III now open  ·  Impact Factor 7.010  ·  Indexed in HeinOnline, Manupatra & Google Scholar + 1000+ Libraries  ·  Free DOI Submit Now →
Chat with us